Document is current
Any future updates will be listed below
-
Authors
Xue, Lulu https://orcid.org/0000-0001-5719-1336
Hamilton, Alex G. https://orcid.org/0000-0002-9810-5630
Zhao, Gan https://orcid.org/0000-0002-8043-6036
Xiao, Zebin https://orcid.org/0000-0002-3311-7403
El-Mayta, Rakan https://orcid.org/0000-0002-5855-233X
Han, Xuexiang https://orcid.org/0000-0003-0011-5222
Gong, Ningqiang https://orcid.org/0000-0002-9444-8505
Xiong, Xinhong
Xu, Junchao https://orcid.org/0000-0003-0725-8111
Figueroa-Espada, Christian G. https://orcid.org/0000-0003-2700-7678
Shepherd, Sarah J.
Mukalel, Alvin J.
Alameh, Mohamad-Gabriel https://orcid.org/0000-0002-5672-6930
Cui, Jiaxi https://orcid.org/0000-0002-2550-979X
Wang, Karin https://orcid.org/0000-0001-7812-2583
Vaughan, Andrew E. https://orcid.org/0000-0001-5740-643X
Weissman, Drew
Mitchell, Michael J. https://orcid.org/0000-0002-3628-2244
-
Funding
Funding for this research was provided by:
Burroughs Wellcome Fund
U.S. Department of Health & Human Services | National Institutes of Health
- License Information
-
More Information
Article History
Received: 25 May 2023
Accepted: 22 January 2024
First Online: 29 February 2024
Change Date: 15 March 2024
Change Type: Update
Change Details: In Figure 1a of this article, the text “Lung-targeted LNP platforms” was not displaying properly. The original article has been corrected.
Competing interests
: L.X. and M.J.M. have filed a patent application on this research. D.W. is named on patents that describe the use of nucleoside-modified mRNA as a platform to deliver therapeutic proteins and vaccines. D.W. and M.G.A. are named on patents describing the use of lipid nanoparticles for nucleic acid delivery. The other authors declare no competing interests.
